DR. BRIAN AUGUST REICHARDT M.D.
Prescription History 1689802001
Internal Medicine - Critical Care Medicine in O Fallon, IL


Quality Rating: 94.61 out of 100 score

NPI Status: Active since June 24, 2009

Contact Information

3 SAINT ELIZABETH BLVD
O FALLON, IL
ZIP 62269
Phone: (618) 641-5803
Fax: (618) 607-5116

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. BRIAN AUGUST REICHARDT M.D., an active Critical Care Medicine specialist practicing in O Fallon, IL. Our medical registry currently tracks 35 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 3,951 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 823 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 54
30-Day Fills 54.0
Days Supply 1,620
IL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply930
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 145.5% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,253.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$467.65

State Avg Cost Per Claim

$591.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 45
30-Day Fills 53.0
Days Supply 1,590
IL State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply811
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 125.0% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,971.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$532.69

State Avg Cost Per Claim

$632.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 515
30-Day Fills 611.7
Days Supply 15,177
IL State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills62.6
Peer Average Days Supply1,500
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 909.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,481.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.94

State Avg Cost Per Claim

$50.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 196
30-Day Fills 247.0
Days Supply 7,410
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,267
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 493.9% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $121,153.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$618.13

State Avg Cost Per Claim

$602.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
IL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills30.7
Peer Average Days Supply916
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,819.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$264.54

State Avg Cost Per Claim

$323.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Asmanex

Generic Formulation: Mometasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 271
IL State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply678
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,452.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$203.08

State Avg Cost Per Claim

$326.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.

Therapeutic Applications

Mometasone is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 34.9
Days Supply 989
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills50.4
Peer Average Days Supply1,456
Conservative Utilization

This provider writes prescriptions for this formulation 42.4% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $822.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.31

State Avg Cost Per Claim

$47.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 179
30-Day Fills 291.5
Days Supply 7,845
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply300
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 442.4% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,725.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.40

State Avg Cost Per Claim

$9.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Bevespi Aerosphere

Generic Formulation: Glycopyrrolate/Formoterol FumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IL State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills25.1
Peer Average Days Supply751
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,488.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$457.34

State Avg Cost Per Claim

$509.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 287
30-Day Fills 331.0
Days Supply 9,930
IL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills45.7
Peer Average Days Supply1,356
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 744.1% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140,290.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$488.82

State Avg Cost Per Claim

$538.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 187
30-Day Fills 215.1
Days Supply 6,435
IL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply1,260
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 450.0% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $144,450.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$772.46

State Avg Cost Per Claim

$785.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 27.0
Days Supply 810
IL State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.7
Peer Average Days Supply612
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 35.3% more claims than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,124.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$309.76

State Avg Cost Per Claim

$361.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 25.0
Days Supply 750
IL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply684
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,904.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$860.27

State Avg Cost Per Claim

$614.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Daliresp

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.3
Days Supply 383
IL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills33.6
Peer Average Days Supply951
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,986.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$498.89

State Avg Cost Per Claim

$555.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.0
Days Supply 540
IL State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills21.7
Peer Average Days Supply646
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,292.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$524.37

State Avg Cost Per Claim

$415.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Dupixent Syringe

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
IL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply562
Conservative Utilization

This provider writes prescriptions for this formulation 26.3% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,960.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,854.30

State Avg Cost Per Claim

$3,702.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fasenra Pen

Generic Formulation: BenralizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 53.6
Days Supply 1,596
IL State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply833
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 82.4% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $188,882.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,092.97

State Avg Cost Per Claim

$5,942.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Benralizumab is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 189
30-Day Fills 376.0
Days Supply 11,279
IL State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills84.4
Peer Average Days Supply2,522
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 302.1% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,181.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.54

State Avg Cost Per Claim

$18.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 63
30-Day Fills 95.0
Days Supply 2,850
IL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply845
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 231.6% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,906.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$284.24

State Avg Cost Per Claim

$243.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 92
30-Day Fills 94.0
Days Supply 2,820
IL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply1,050
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 228.6% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35,897.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$390.19

State Avg Cost Per Claim

$462.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 60
30-Day Fills 124.4
Days Supply 3,707
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills49.6
Peer Average Days Supply1,306
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 81.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,103.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.06

State Avg Cost Per Claim

$51.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 113
IL State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.0
Peer Average Days Supply205
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $166.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.59

State Avg Cost Per Claim

$8.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 170
30-Day Fills 376.9
Days Supply 11,301
IL State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills121.5
Peer Average Days Supply3,592
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 214.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,718.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.99

State Avg Cost Per Claim

$17.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nucala

Generic Formulation: MepolizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 68
30-Day Fills 68.0
Days Supply 1,904
IL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply554
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 257.9% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $266,431.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,918.11

State Avg Cost Per Claim

$4,017.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 69
30-Day Fills 77.1
Days Supply 797
IL State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills55.3
Peer Average Days Supply1,013
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 53.3% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $151.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.20

State Avg Cost Per Claim

$6.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Rifampin

Generic Formulation: RifampinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 34.6
Days Supply 1,000
IL State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills21.9
Peer Average Days Supply605
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $616.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.82

State Avg Cost Per Claim

$71.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 65
30-Day Fills 77.0
Days Supply 2,206
IL State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply652
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 333.3% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,481.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$176.63

State Avg Cost Per Claim

$333.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ropinirole Hcl

Generic Formulation: Ropinirole HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 81.0
Days Supply 2,430
IL State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills58.6
Peer Average Days Supply1,695
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $508.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.74

State Avg Cost Per Claim

$21.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to treat Parkinson's disease. It can improve your ability to move and decrease shakiness (tremor), stiffness, slowed movement, and unsteadiness. It may also decrease the number of episodes of not being able to move (on-off syndrome). Ropinirole works by helping to restore the balance of a certain natural substance (dopamine) in the brain.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 95
30-Day Fills 149.0
Days Supply 4,470
IL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply964
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 331.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81,346.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$856.28

State Avg Cost Per Claim

$755.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 72.0
Days Supply 2,160
IL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills41.3
Peer Average Days Supply1,236
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.7% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,719.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$823.82

State Avg Cost Per Claim

$679.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 300
30-Day Fills 380.0
Days Supply 11,400
IL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills48.7
Peer Average Days Supply1,458
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 782.4% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $159,085.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$530.29

State Avg Cost Per Claim

$541.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Tezspire

Generic Formulation: Tezepelumab-EkkoSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 616
IL State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.5
Peer Average Days Supply406
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $101,678.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,621.76

State Avg Cost Per Claim

$3,990.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used with other medications to control and prevent symptoms of severe asthma (such as wheezing and shortness of breath). Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Tezepelumab belongs to a class of medications known as monoclonal antibodies. It helps reduce swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 823
30-Day Fills 1,025.0
Days Supply 30,750
IL State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills68.3
Peer Average Days Supply2,042
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,513.7% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $696,079.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$845.78

State Avg Cost Per Claim

$870.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 106
30-Day Fills 120.3
Days Supply 2,983
IL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills32.9
Peer Average Days Supply775
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 278.6% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,178.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.16

State Avg Cost Per Claim

$76.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 56
30-Day Fills 84.0
Days Supply 2,520
IL State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills30.6
Peer Average Days Supply918
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 180.0% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,155.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$306.36

State Avg Cost Per Claim

$263.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. BRIAN AUGUST REICHARDT M.D. provides transparency into local medical care patterns within O Fallon, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.